Advertisement

Progestins and Oral Contraceptives

  • John A. Thomas
  • Edward J. Keenan

Abstract

Development and maintenance of the female reproductive system are dependent on the cyclical interaction between estrogens, primarily es-tradiol-17β, and progesterone. The principal target tissues for these steroid hormones include the uterus, vagina, fallopian tubes, and mammary glands, as well as the anterior pituitary and hypothalamus. Although estrogens are recognized as promoters of cellular proliferation, progestins are known to facilitate cellular differentiation. In addition, progesterone and related drugs exert significant antiestrogenic effects. It is the balance between estrogen and progesterone actions that regulates the state of the female reproductive system. Some of the therapeutically useful derivatives of progesterone share a structural similarity to androgens, and these agents in some instances also produce androgenic or antiandrogenic activity.

Keywords

Progesterone Receptor Luteinizing Hormone Oral Contraceptive Corpus Luteum Uterine Bleeding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Recommended Readings

Physiology and Pharmacology of the Progestins

  1. Benagiano, G., Zulli, P., and Diczfalusy, E., Progestogens in therapy, Serono Symp. Ser. 3:1–270, 1983.Google Scholar
  2. Chan, L., and O’Malley, B. W., Mechanism of action of the sex steroid hormones, N. Engl. J. Med. 294:1322, 1976.PubMedCrossRefGoogle Scholar
  3. Edgren, R. A., Progestagens, in: Clinical Use of Sex Steroids (J. R. Givens, ed.), pp. 1–29, Year Book Medical Publishers, Chicago, 1979.Google Scholar
  4. Gambrell, R.D., Menopause: Benefits and risks of estrogen-progestogen replacement therapy, Fertil. Steril. 37:457, 1982.PubMedGoogle Scholar
  5. Gambrell, R. D., Proposal to decrease the risk and improve the prognosis of breast cancer, Am. J. Obstet. Gynecol. 150:119, 1984.PubMedGoogle Scholar
  6. Gambrell, R. D., Bagnell, C. A., and Greenblatt, R. B., Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review, Am. J. Obstet. Gynecol. 146:696, 1983.PubMedGoogle Scholar
  7. Gold, R. B., and Wilson, P. D., Depo-Provera: New development in decade-old controversy, Fam. Plann. Perspect. 13:35, 1981.PubMedCrossRefGoogle Scholar
  8. Grody, W. W., Schrader, W. T., and O’Malley, B. W., Activation, transformation and subunit structure of steroid hormone receptors, Endocrine Rev. 3:141, 1982.CrossRefGoogle Scholar
  9. Horowitz, K. B., Wey, L. L., Sedlacek, S. M., and d’Arville, C. N., Progestin action and progesterone receptor structure in human breast cancer: A review, Recent Prog. Horm. Res. 41:249–317, 1985.Google Scholar
  10. Keenan, E. J., The physiological and pathophysiological significance of steroid hormone receptors, Gynecol. Obstet. 5:343, 1982.Google Scholar
  11. Knobil, E., The neuroendocrine control of the menstrual cycle, Recent Prog. Horm. Res. 36:53, 1980.PubMedGoogle Scholar
  12. McCarty, K. S., Jr., Lubahn, D. B., and McCarty, K. S., Sr., Estrogen and progesterone receptors: Physiological and pathological considerations, Clin. Endocrinol. Metab. 12:133, 1983.PubMedCrossRefGoogle Scholar
  13. McGuire, W. L., and Clark, G. M., Role of progesterone receptors in breast cancer, J. Sem. Oncol. 12:12–16, 1985.Google Scholar
  14. Neumann, F., Progestogens: A short review, Postgrad. Med. J. (Suppl. 2) 54:11, 1978.Google Scholar
  15. O’Malley, B. W., Steroid hormone action in eukaryotic cells, J. Clin Invest. 74:307, 1984.PubMedCrossRefGoogle Scholar
  16. Renoir, J. M., and Mester, J., Chick oviduct progesterone receptor: Structure, immunology, function, Mol. Cell Endocrinol. 37:1, 1984.PubMedCrossRefGoogle Scholar
  17. Richards, J. S., Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation, Physiol. Rev. 60:51, 1980.PubMedGoogle Scholar
  18. Rochefort, H., and Chalbos, D., Progestin-specific markers in human cell lines: Biological and pharmacological applications, Mol. Cell Endocrinol. 36:36, 1984.CrossRefGoogle Scholar
  19. Whitehead, M. I., Townsend, P. T., Pryse-Davies, J., Ryder, T. A., and King, R. J. B., Effects of estrogens and progestins on biochemistry and morphology of postmenopausal endometrium, N. Engl. J. Med. 305:1599, 1981.PubMedCrossRefGoogle Scholar
  20. Wilson, J. C., and Brent, R. L., Are female sex hormones teratogenic?, Am. J. Obstet. Gynecol. 141:567, 1981.PubMedGoogle Scholar

Pharmacology of the Oral Contraceptives

  1. Andrews, W. C., Oral contraception: Physiologic and pathologic effects, Obstet. Gynecol. Ann. 7:325:1981.Google Scholar
  2. Back, D. J., Breckenridge, A. M., Crawford, F. E., MacIver, M., Orme, M. L. E., and Rowe, P. H., Interindividual variation and drug interactions with hormonal steroid contraceptives, Drugs 21:46, 1981.PubMedCrossRefGoogle Scholar
  3. Benagiano, G., and Primiero, F. M., Long acting contraceptives: Present status, Drugs 25:570, 1983.PubMedCrossRefGoogle Scholar
  4. Bronson, R. A., Oral contraception: Mechanism of action, Clin. Obstet. Gynecol. 24:869, 1981.PubMedCrossRefGoogle Scholar
  5. Centers for Disease Control, Cancer and Steroid Hormone Study: Oral Contraceptive use and the risk of endometrial cancer, JAMA 249:1600, 1983.CrossRefGoogle Scholar
  6. Centers for Disease Control, Cancer and Steroid Hormone Study, Oral contraceptive use and the risk of ovarian cancer, JAMA 249:1596, 1983.CrossRefGoogle Scholar
  7. Centers for Disease Control, Cancer and Steroid Hormone Study, Long-term oral contraceptive use and risk of breast cancer, JAMA 249:1591, 1983.CrossRefGoogle Scholar
  8. Dalen, J. E., and Hickler, R. B., Oral contraceptives and cardiovascular disease, Am. Heart J. 101:626, 1981.PubMedCrossRefGoogle Scholar
  9. Delia, J. E., and Emery, M. G., Clnical pharmacology and common minor side effects of oral contraceptives, Clin Obstet. Gynecol. 24:879, 1981.PubMedCrossRefGoogle Scholar
  10. Diczfalusy, E., Gregory Pincus and steroidal contraception: A new departure in the history of mankind, J. Steroid Biochem 11:3, 1979.PubMedCrossRefGoogle Scholar
  11. Dixon, G. W., Schlesselman, J. S., Ory, H. W., and Blye, R. P., Ethinylestradiol and conjugated estrogens as postcoital contraceptives, JAMA 244:1336, 1980.PubMedCrossRefGoogle Scholar
  12. Dorflinger, L. J., Relative potency of progestins used in oral contraceptives, Contraception 31:557–570, 1985.PubMedCrossRefGoogle Scholar
  13. Droegemaueller, W., and Bressler, R., Effectiveness and risks of contraception, Annu. Rev. Med. 31:329, 1980.CrossRefGoogle Scholar
  14. Edgren, R. A. Progestational potency of oral contraceptives: A polemic, Int. J. Fertil. 23:162, 1978.PubMedGoogle Scholar
  15. Edgren, R. A., and Sturtevant, F. M., Potencies of oral contraceptives, Am. J. Obstet. Gynecol. 125:1029, 1976.PubMedGoogle Scholar
  16. Goldzieher, J. W., Estrogens in oral contraceptives: Historical perspectives, Johns Hopkins Med. J. 150:165, 1982.PubMedGoogle Scholar
  17. Greenblatt, R. B., Oral contraceptives: The state of the art, Clin. Ther. 8:6, 1985.PubMedGoogle Scholar
  18. McQueen, E. G., Hormonal steroid contraceptives: A further review of adverse reactions, Drugs 16:322, 1978.PubMedCrossRefGoogle Scholar
  19. McQueen, E. G., The long term safety of hormonal steroid contraceptives, Drugs 16:460, 1981.CrossRefGoogle Scholar
  20. Mishell, D. R., Non-contraceptive health benefits of oral steroid contraceptives, Am. J. Obstet. Gynecol. 142:809, 1982.PubMedGoogle Scholar
  21. Realini, J. P., and Goldzieher, J. W., Oral contraceptives and cardiovascular disease: A critique of the epidemiologic studies, Am. J. Obstet. Gynecol. 152:729, 1985.PubMedGoogle Scholar
  22. Smith, M. A., and Youngkin, E. Q., Current perspectives on combination oral contraceptives, Clin. Pharm. 3:485, 1984.PubMedGoogle Scholar
  23. Speroff, L., The formulation of oral contraceptives: Does the amount of estrogen make any clinical difference?, Johns Hopkins Med. J. 150:170, 1982.PubMedGoogle Scholar
  24. Stadel, B. V., Oral contraceptives and cardiovascular disease, N. Engl. J. Med. 305:612 (pt. 1), 672 (pt. 2), 1981.PubMedCrossRefGoogle Scholar
  25. Upton, G. V., The phasic approach to oral contraception: The triphasic concept and its application, Int. J. Fertil. 28:121, 1983.PubMedGoogle Scholar
  26. Wilson, E. A., Steroid contraception, in: Clinical Use of Sex Steroid (J. R. Givens, ed.), p. 117, Year Book Medical Publishers, Chicago, 1980.Google Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • John A. Thomas
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
  • Edward J. Keenan
    • 7
    • 8
    • 9
    • 10
  1. 1.Corporate ResearchTravenol Laboratories, Inc.Round LakeUSA
  2. 2.Department of PharmacologyNorthwestern University School of MedicineChicagoUSA
  3. 3.Department of UrologyNorthwestern University School of MedicineChicagoUSA
  4. 4.Department of Pharmacology and ToxicologyWest Virginia School of MedicineMorgantownUSA
  5. 5.Department of PharmacologyUniversity of Illinois School of MedicineChicagoUSA
  6. 6.Department of PharmacologyRush-Presbyterian School of MedicineChicagoUSA
  7. 7.Hormone Receptor Laboratory, School of MedicineThe Oregon Health Sciences UniversityPortlandUSA
  8. 8.Department of Surgery, School of MedicineThe Oregon Health Sciences UniversityPortlandUSA
  9. 9.Department of Pharmacology, School of MedicineThe Oregon Health Sciences UniversityPortlandUSA
  10. 10.Department of Medicine (Medical Oncology), School of MedicineThe Oregon Health Sciences UniversityPortlandUSA

Personalised recommendations